The BioInsights Podcast
Episodes
63 episodes
Accelerating cures: funding stem cell innovation & ideas in an evolving cell therapy space
The Maryland Stem Cell Research Fund (MSCRF) is a well-established US state fund aimed specifically at driving the development of new medical strategies for the prevention, diagnosis, treatment and cure of human diseases, injuries, and conditio...
Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us
Achieving better AAV vector productivity and product quality
Transient transfection of plasmids into suspension HEK293 cells is still the most commonly used method for the production of recombinant adeno-associated virus (rAAV) gene therapies – in this episode, Diane Golebiowski and Marissa Stanvick disc...
Partnering in life sciences: what is the ‘secret sauce’ for success? PART 2
Welcome to a 2-part series in which we identify and distill some key learnings for partnering success in today's life sciences sector.Perhaps one of the most valuable take-aways from the COVID-19 pandemic response is the sheer sc...
Partnering in life sciences: what is the secret sauce for success? PART 1: The Big Pharma perspective
PART 1: The Big Pharma PerspectiveWelcome to a 2-part series in which we identify and distill some key learnings for partnering success in today's life sciences sector.Perhaps one of the most valuable take-aways from the ...
Where will tomorrow’s workforce come from? PART 4: Who are tomorrow’s cell and gene therapy workers?
PART 4: Who are tomorrow’s cell and gene therapy workers?Welcome to a 4-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment: “Where will tomorrow’s workforce come from?...
Where will tomorrow’s workforce come from? PART 3: Innovation in staff sourcing, training and retention - what works and what doesn’t?
PART 3: Innovation in staff sourcing, training and retention - what works and what doesn’t? Welcome to a 4-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment: “Where ...
Where will tomorrow’s workforce come from? PART 2: How is the educational system responding, and how can the cell and gene therapy community at large help?
Part 2: How is the educational system responding, and how can the cell and gene therapy community at large help?Welcome to a four-part series exploring a question that the entire cell and gene therapy community is struggling with at ...
Where will tomorrow’s workforce come from? PART1: Framing the issue
Welcome to a 4-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment: “Where will tomorrow’s workforce come from?”The cell and gene therapy field has been advancing ...
The quest for the Holy Grail in AAV chromatography: empty–full separation
Ratish Krishnan and Oliver Rammo share their thoughts on the need for a more nuanced understanding of AAV capture and empty–full separation, and the trends driving innovation in this area.
Residual DNA testing in viral vector manufacture: exploring the challenges and solutions
In this episode Ilaria Scarfone Field Application Specialist, Pharma Analytics, Thermo Fisher Scientific speaks to Mike Brewer, Director and Global Principal Consultant, BioProduction Division, Thermo Fisher Scientific abou...
Precisely for CGT: automating aseptic filling for lowest volumes
In this Episode, Roisin McGuigan, Editor at BioInsights, speaks to Dr Barbara Fisher, Process Consultant at Single Use Support about automating aseptic filling for lowest volumes. Barbara works with both established pharmaceutical manufacturers...